NCT04264182

Brief Summary

This study will evaluate the utilization of an ultra-conservative programming strategy to reduce shocks for ventricular arrhythmias (VA) among patients with heart failure, an implantable cardioverter-defibrillator (ICD) and continuous flow (CF) left ventricular assist device (LVAD). Patients on LVAD support demonstrate unique hemodynamic tolerability of VA, and the role for ICDs among patients with newer generation CF LVADs remains less clear than the older generation devices. Prior studies have explored extended detection ICD programming to reduce unecessary or potentially avoidable shocks to patients. However, no prospective randomized study to-date has evaluated such programming strategies in the CF LVAD patient population. The study hypothesis is that ultra-conservative (UC) ICD programming will result in a reduction of shocks and an improvement in quality of life without increasing hospitalizations, syncope or death among patients on CF LVAD support, and the primary design is a 1:1 randomization between UC programming over standard, physician discretion programming.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
11

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Feb 2020

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

January 31, 2020

Completed
3 days until next milestone

Study Start

First participant enrolled

February 3, 2020

Completed
8 days until next milestone

First Posted

Study publicly available on registry

February 11, 2020

Completed
2.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 4, 2022

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

April 4, 2022

Completed
Last Updated

June 8, 2022

Status Verified

June 1, 2022

Enrollment Period

2.2 years

First QC Date

January 31, 2020

Last Update Submit

June 6, 2022

Conditions

Keywords

LVADICDShockVentricular arrhythmia

Outcome Measures

Primary Outcomes (3)

  • ICD shock delivery

    Number of patients with ICD shock delivery

    Up to 24 months

  • Mortality

    Incidence of all-cause death

    Up to 24 Months

  • Syncope

    Individual occurrence of loss of consciousness

    Up to 24 Months

Secondary Outcomes (4)

  • Time to first ICD shock

    Up to 24 Months

  • Time to first ICD shock for VT/VF (appropriate shock)

    Up to 24 Months

  • Standard INTERMACS survey

    Up to 24 Months

  • Hospitalization

    Up to 24 Months

Study Arms (2)

Ultra-conservative ICD programming

EXPERIMENTAL

Single VF zone programming strategy with maximal detection extension to avoid ICD shock delivery with monitoring-only VT detection zones

Other: ICD programming

Standard programming (physician discretion)

NO INTERVENTION

Usual care ICD programming, which is historically unchanged from ICD programming pre-LVAD

Interventions

Re-programming of the ICD device for VA detection (see above)

Ultra-conservative ICD programming

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Pre-existing ICD
  • LVAD placement

You may not qualify if:

  • Non-functional ICD system
  • Uncontrolled ventricular arrhythmias within 7 days of enrollment (defined as VT/VF \>30 seconds and/or causing hemodynamic instability and/or symptoms of pre-syncope or syncope)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Cleveland Clinic

Cleveland, Ohio, 44195, United States

Location

MeSH Terms

Conditions

Heart Failure, SystolicShock

Condition Hierarchy (Ancestors)

Heart FailureHeart DiseasesCardiovascular DiseasesPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

  • Daniel Cantillon, M. D.

    The Cleveland Clinic

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: Prospective. Randomized control trial.
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

January 31, 2020

First Posted

February 11, 2020

Study Start

February 3, 2020

Primary Completion

April 4, 2022

Study Completion

April 4, 2022

Last Updated

June 8, 2022

Record last verified: 2022-06

Data Sharing

IPD Sharing
Will not share

Locations